Boston Scientific Corporation $BSX Shares Purchased by Brookstone Capital Management

Brookstone Capital Management grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 183,197 shares of the medical equipment provider’s stock after buying an additional 53,876 shares during the period. Brookstone Capital Management’s holdings in Boston Scientific were worth $17,468,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of BSX. Steph & Co. purchased a new position in shares of Boston Scientific in the 3rd quarter worth $25,000. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp raised its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth approximately $26,000. Finally, United Community Bank lifted its position in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 9.1%

Shares of NYSE:BSX opened at $62.90 on Tuesday. The company has a market cap of $93.49 billion, a PE ratio of 32.42, a price-to-earnings-growth ratio of 1.07 and a beta of 0.69. The firm has a 50 day simple moving average of $76.94 and a 200 day simple moving average of $90.32. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52 week low of $61.24 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of analyst reports. Truist Financial reduced their price target on Boston Scientific from $95.00 to $92.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. National Bank Financial set a $115.00 price target on Boston Scientific in a research report on Monday, February 2nd. Citigroup lowered their price objective on Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Finally, Oppenheimer cut their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Asurys fluid management system gives Boston Scientific another regulatory win and supports growth in perioperative/OR product offerings. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Strong HI-PEITHO trial results for the EKOS endovascular system (positive readout reported) bolster the company’s pulmonary embolism franchise and provide clinical momentum for EKOS adoption. Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
• Positive Sentiment: Several analysts reaffirm buy/outperform ratings and high price targets (Needham, TD Cowen, RBC), reflecting confidence in long-term growth drivers like Watchman FLX and diversified product mix. Buy Rating on Boston Scientific’s Watchman FLX
• Neutral Sentiment: Company set an investors’ conference call for the Q1 2026 results (April 22), which will be a key event for management to clarify guidance, procedure trends and margin outlook. Boston Scientific announces conference call
• Neutral Sentiment: Analysts expect single-digit EPS growth for Q1 2026; Q1 results and any guidance update will likely drive near-term volatility but may not change the long-term thesis. Boston Scientific’s Q1 2026 Earnings: What to Expect
• Negative Sentiment: Mixed/underwhelming clinical data for the Watchman device (conflicting trial readouts) is the proximate trigger for today’s sell-off as investors reprice stroke-prevention growth expectations. Boston Scientific Falls After Underwhelming Trial Results
• Negative Sentiment: Raymond James downgraded BSX and cut its price target, and Goldman trimmed its target as well — analyst downgrades and lower PTs pressured sentiment and valuation multiples. Shares Plunge After Raymond James Downgrade
• Negative Sentiment: Heightened legal/regulatory overhang — multiple investor alerts and class-action filings tied to prior disclosures are creating uncertainty and may keep pressure on the stock until resolved. BSX Investor Alert: Securities Fraud Lawsuit

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.